IGF2 and ovarian serous adenocarcinoma: To confirm the clinical relevance of our findings, an analysis of the serous ovarian cancer cohort of The Cancer Genome Atlas (TCGA) was done to evaluate the relation of IGF2 expression and clinical outcomes.